NASDAQ:CCXI - ChemoCentryx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.25
  • Forecasted Upside: 28.70 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$50.70
▲ +0.1 (0.20%)

This chart shows the closing price for CCXI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ChemoCentryx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CCXI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CCXI

Analyst Price Target is $65.25
▲ +28.70% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for ChemoCentryx in the last 3 months. The average price target is $65.25, with a high forecast of $110.00 and a low forecast of $38.00. The average price target represents a 28.70% upside from the last price of $50.70.

This chart shows the closing price for CCXI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in ChemoCentryx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/18/2021
  • 1 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/19/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/17/2021
  • 1 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/15/2021
  • 1 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/13/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/14/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/13/2022
  • 1 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2022Stifel NicolausDowngradeBuy ➝ HoldLow
8/5/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$52.00Low
8/5/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$64.00 ➝ $52.00Low
8/5/2022HC WainwrightDowngradeBuy ➝ Neutral$101.00 ➝ $52.00Low
8/4/2022Canaccord Genuity GroupInitiated CoverageBuy$81.00N/A
3/18/2022Stifel NicolausReiterated RatingBuy ➝ Buy$85.00Medium
11/10/2021Raymond JamesBoost Price TargetStrong-Buy$107.00 ➝ $110.00High
11/9/2021SVB LeerinkReiterated RatingBuyHigh
10/11/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$14.00 ➝ $38.00High
10/11/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$17.00 ➝ $64.00High
10/8/2021HC WainwrightBoost Price TargetBuy$28.00 ➝ $101.00High
10/8/2021Stifel NicolausBoost Price TargetBuy$31.00 ➝ $85.00High
10/8/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$62.00 ➝ $107.00High
10/8/2021Piper SandlerUpgradeNeutral ➝ Overweight$25.00 ➝ $52.00High
7/6/2021Stifel NicolausUpgradeHold ➝ Buy$26.00 ➝ $31.00Low
5/13/2021JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight$57.00 ➝ $17.00Low
5/13/2021Stifel NicolausReiterated RatingBuy ➝ Hold$93.00 ➝ $26.00Low
5/13/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$84.00 ➝ $17.00Low
5/13/2021Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$120.00 ➝ $51.00Low
5/12/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$80.00 ➝ $25.00N/A
5/7/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$120.00 ➝ $51.00High
5/7/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$84.00 ➝ $17.00High
5/7/2021Stifel NicolausDowngradeBuy ➝ Hold$93.00 ➝ $26.00High
5/7/2021HC WainwrightLower Price TargetBuy$101.00 ➝ $28.00High
5/7/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$57.00 ➝ $17.00High
5/6/2021Piper SandlerDowngradeOverweight ➝ Neutral$80.00 ➝ $25.00High
3/2/2021Raymond JamesBoost Price TargetStrong-Buy$119.00 ➝ $120.00Medium
3/2/2021HC WainwrightBoost Price TargetBuy$83.00 ➝ $101.00Medium
3/1/2021Stifel NicolausInitiated CoverageBuy$93.00Medium
1/8/2021Raymond JamesBoost Price TargetStrong-Buy$100.00 ➝ $119.00Medium
10/29/2020Wells Fargo & CompanyLower Price TargetOverweight$79.00 ➝ $70.00High
10/29/2020Piper SandlerBoost Price TargetOverweight$67.00 ➝ $71.00High
10/29/2020SVB LeerinkBoost Price TargetOutperform$75.00 ➝ $84.00High
10/29/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$63.00 ➝ $60.00High
9/17/2020HC WainwrightBoost Price Target$73.00 ➝ $85.00High
8/12/2020SVB LeerinkBoost Price TargetOutperform$65.00 ➝ $75.00High
8/11/2020Raymond JamesBoost Price TargetStrong-Buy$95.00 ➝ $100.00High
7/29/2020JPMorgan Chase & Co.Lower Price TargetOverweight$64.00 ➝ $61.00Medium
6/16/2020BTIG ResearchInitiated CoverageBuy$70.00Medium
5/27/2020Wells Fargo & CompanyInitiated CoverageOverweight$79.00High
5/18/2020HC WainwrightReiterated RatingBuy$69.00High
5/18/2020Piper SandlerBoost Price TargetReduce ➝ Overweight$54.00 ➝ $70.00High
5/14/2020JPMorgan Chase & Co.Boost Price TargetOverweight$61.00 ➝ $64.00High
5/12/2020SVB LeerinkBoost Price TargetOutperform$54.00 ➝ $65.00Medium
5/12/2020Raymond JamesBoost Price TargetStrong-Buy$38.00 ➝ $102.00Medium
5/12/2020HC WainwrightBoost Price TargetBuy$60.00 ➝ $69.00High
4/2/2020SVB LeerinkInitiated CoverageBuy$54.00Medium
4/1/2020SVB LeerinkReiterated RatingOutperformHigh
3/11/2020SVB LeerinkReiterated RatingOutperformHigh
3/11/2020JPMorgan Chase & Co.Boost Price TargetOverweight$60.00 ➝ $61.00High
3/11/2020Raymond JamesBoost Price TargetStrong-Buy$56.00 ➝ $64.00High
3/11/2020HC WainwrightReiterated RatingBuyHigh
2/18/2020JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Positive$28.00 ➝ $60.00High
1/24/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $60.00Low
11/26/2019Raymond JamesBoost Price TargetStrong-Buy$17.00 ➝ $56.00Medium
11/26/2019JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Positive$14.00 ➝ $28.00N/A
11/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$17.00 ➝ $54.00N/A
11/26/2019HC WainwrightBoost Price TargetBuy ➝ Buy$23.00 ➝ $40.00N/A
10/15/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
9/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$16.00 ➝ $14.00High
6/6/2019Raymond JamesLower Price TargetStrong-Buy$24.00 ➝ $17.00High
5/7/2019HC WainwrightReiterated RatingBuy$23.00High
4/23/2019Raymond JamesSet Price TargetBuy$22.00Low
3/27/2019B. RileyUpgradeNeutral ➝ Buy$12.50 ➝ $22.00High
2/14/2019SVB LeerinkReiterated RatingOutperformN/A
2/11/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$20.00High
1/8/2019B. RileyInitiated CoverageNeutral$12.50Low
9/7/2018B. RileyInitiated CoverageNeutral ➝ Neutral$12.50High
8/14/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$14.00 ➝ $15.00High
8/13/2018HC WainwrightReiterated RatingBuy$20.00High
6/28/2018Raymond JamesInitiated CoverageStrong-Buy$18.00High
5/10/2018CowenReiterated RatingHoldMedium
5/2/2018HC WainwrightInitiated CoverageBuy ➝ Buy$20.00Low
3/13/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$13.00 ➝ $16.00Medium
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/14/2022
  • 10 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/13/2022
  • 3 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
4/14/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
5/14/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/13/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/13/2022
  • 9 very positive mentions
  • 27 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 9 very positive mentions
  • 27 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
ChemoCentryx logo
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $50.70
Low: $50.58
High: $50.80

50 Day Range

MA: $27.55
Low: $22.17
High: $50.89

52 Week Range

Now: $50.70
Low: $13.11
High: $51.06

Volume

132,149 shs

Average Volume

3,691,797 shs

Market Capitalization

$3.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of ChemoCentryx?

The following Wall Street analysts have issued research reports on ChemoCentryx in the last twelve months: Canaccord Genuity Group Inc., HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Raymond James, Stifel Nicolaus, StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for CCXI.

What is the current price target for ChemoCentryx?

8 Wall Street analysts have set twelve-month price targets for ChemoCentryx in the last year. Their average twelve-month price target is $65.25, suggesting a possible upside of 29.0%. Raymond James has the highest price target set, predicting CCXI will reach $110.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $38.00 for ChemoCentryx in the next year.
View the latest price targets for CCXI.

What is the current consensus analyst rating for ChemoCentryx?

ChemoCentryx currently has 5 hold ratings, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CCXI will outperform the market and that investors should add to their positions of ChemoCentryx.
View the latest ratings for CCXI.

What other companies compete with ChemoCentryx?

How do I contact ChemoCentryx's investor relations team?

ChemoCentryx's physical mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company's listed phone number is (650) 210-2900 and its investor relations email address is [email protected] The official website for ChemoCentryx is www.chemocentryx.com. Learn More about contacing ChemoCentryx investor relations.